Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.